Until recently, IFN-ß was the only DMT approved by the United Kingdom National Institute for Clinical Excellence (NICE) for people with SPMS, but only in the case of patients experiencing continuing relapses (i.e., active SPMS) (La Mantia et al., 2013). Here, IFNA1 is linked to secondary progressive multiple sclerosis.